Second Annual: Structuring, Negotiating and Managing

Pharmaceutical/Biotech Collaborations

The Next Generation

Monday, May 12, 2003

About

Now more than ever, the ability to successfully collaborate is a critical competency for pharmaceutical and biotech companies. With millions of dollars in future revenue at stake - and in some cases a company's survival - it is imperative that you, as counsel to or executive for a pharmaceutical or biotech company, have an up-to-the-minute and complete understanding of the critical legal, business and management issues required to facilitate a winning life sciences transaction.

American Conference Institute's Second Annual conference materials on Pharmaceutical/Biotech Collaborations will bring you thoughtful and targeted commentary from an outstanding faculty of leading in-house biotech and pharmaceutical counsel and expert attorneys with extensive experience in putting together, managing, salvaging and exiting collaborations. They provided practical information and insights on:
  • Real life examples of successful deals and insights into how these deals were negotiated and structured
  • How to finance and fund a deal today
  • New due diligence concerns
  • How to structure the deal to protect collective and individual IP rights
  • How to form effective co-promotion and co-marketing arrangements
  • Successful troubleshooting for collaborations between: established players, biotechs and industry and academia
And much more

This is by far the most comprehensive program of the year on collaborations. Take this opportunity to get the information that you need from those who have mastered "the art of the deal".

Contents & Contributors

About

Now more than ever, the ability to successfully collaborate is a critical competency for pharmaceutical and biotech companies. With millions of dollars in future revenue at stake - and in some cases a company's survival - it is imperative that you, as counsel to or executive for a pharmaceutical or biotech company, have an up-to-the-minute and complete understanding of the critical legal, business and management issues required to facilitate a winning life sciences transaction.

American Conference Institute's Second Annual conference materials on Pharmaceutical/Biotech Collaborations will bring you thoughtful and targeted commentary from an outstanding faculty of leading in-house biotech and pharmaceutical counsel and expert attorneys with extensive experience in putting together, managing, salvaging and exiting collaborations. They provided practical information and insights on:
  • Real life examples of successful deals and insights into how these deals were negotiated and structured
  • How to finance and fund a deal today
  • New due diligence concerns
  • How to structure the deal to protect collective and individual IP rights
  • How to form effective co-promotion and co-marketing arrangements
  • Successful troubleshooting for collaborations between: established players, biotechs and industry and academia
And much more

This is by far the most comprehensive program of the year on collaborations. Take this opportunity to get the information that you need from those who have mastered "the art of the deal".

Contents & Contributors

MAKING PHARMA AND BIOTECH COLLABORATIONS WORK TO FILL THE PIPELINE: REAL WORLD CHALLENGES AND REAL WORLD SOLUTIONS
Richard Smith, Palmer & Dodge

BIOTECH WITH LEADING TECHNOLOGY AND INTERESTING PRODUCT OPPORTUNITIES!
Dr. Manon M.J. Cox, Protein Sciences Corp.

MAKING PHARMACEUTICAL AND BIOTECH COLLABORATIONS WORK TO FILL THE PIPELINE: REAL WORLD CHALLENGES AND REAL WORLD SOLUTIONS
John A. Westwood, PhD, L.E.K. Consulting

STRUCTURING, DRAFTING AND NEGOTIATING PHARMACEUTICAL AND BIOTECH LICENSES
Adam H. Golden, Kaye Scholer LLP

STRUCTURING THE DEAL: MANAGING PHARMACEUTICAL COLLABORATION RISKS IN THE CONTRACT
David N. Lawson, Gilead Sciences, Inc.

BUSINESS DEVELOPMENT AND THE PROCESS OF PARTNERING
Deanna M. Petersen, Antigenics

MODEL DUE DILIGENCE CHECKLIST
Maureen A. Rogers, Novartis Consumer Health, Inc.

CAN THIS DEAL BE SAVED?
James P. Kappel, Eli Lilly & Co.

EXIT STRATEGIES
Charles Weiss, Kenyon & Kenyon

THE GOVERNANCE AND MANAGEMENT OF COLLABORATIONS
Ira L. Kotel, Dickstein Shapiro Morin & Oshinsky LLP
David L. Lopez, Discovery Laboratories, Inc.

NEW DUE DILIGENCE CONCERNS
Martin Travers, Sanofi-Sythelabo, Inc.

LICENSING AND INTELLECTUAL PROPERTY CONCERNS RELATIVE TO PHARMACEUTICAL & BIOTECHNOLOGY COLLABORATIONS
Patricia A. Schreck, Elan Drug Delivery, a division of Elan Corporation, plc.
Michele M. Simkin, Foley & Lardner

BIOTECHNOLOGY-BIOTECHNOLOGY COLLABORATIONS
Jim J. Kovach, Athersys

SPECIAL CONSIDERATIONS FOR CO-PROMOTION AND CO-MARKETING COLLABORATIONS
Francis V. McNamara, Saul Ewing LLP
Richard Kenny, AstraZeneca Pharmaceuticals LP

COLLABORATIONS BETWEEN ESTABLISHED PLAYERS
Paul A. Thompson, Schering-Plough Corporation

ISSUES UNIQUE TO INDUSTRY/UNIVERSITY COLLABORATIONS
Susan Galli, Ropes & Gray
Jonathan Lourie, Edwards & Angell, LLP

STRUCTURING AND DRAFTING A "WIN-WIN" COLLABORATION AGREEMENT
William F. Lawrence, Frommer Lawrence & Haug LLP
Thomas J. Kowalski, Frommer Lawrence & Haug LLP


DOCUMENT TYPES: PRESENTATIONS AVAILABLE: 0